argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
September 03 2019 - 1:00AM
September 3, 2019
Breda, the Netherlands / Ghent,
Belgium – argenx (Euronext & Nasdaq: ARGX), a
clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe
autoimmune diseases and cancer, today announced that Tim Van
Hauwermeiren, Chief Executive Officer, will present at the
Morgan Stanley 17th Annual Global Healthcare Conference on Monday,
September 9, 2019 at 10:30 am ET in New York.
The live webcast may be accessed on the homepage
of the argenx website at www.argenx.com. Shortly after the
presentation, a replay of the webcast will be available for 90 days
on the argenx website.
About argenxargenx is a
clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe
auto-immune diseases and cancer. The company is focused on
developing product candidates with the potential to be either
first-in-class against novel targets or best-in-class against
known, but complex, targets in order to treat diseases with a
significant unmet medical need. argenx’s ability to execute on this
focus is enabled by its suite of differentiated technologies. The
SIMPLE Antibody™ Platform, based on the powerful llama immune
system, allows argenx to exploit novel and complex targets, and its
three complementary Fc engineering technologies are designed to
expand the therapeutic index of its product candidates.
www.argenx.com
For further information, please contact:
Beth DelGiacco, Vice President, Investor Relations +1 518 424
4980bdelgiacco@argenx.com
Marieke Vermeersch, Corporate Communications & Investor
Relations Consultant+32 (0)479 490 603+32 (0)3 290 00
50mvermeersch@argenx.com
Forward-looking Statements
The contents of this announcement include
statements that are, or may be deemed to be, “forward-looking
statements.” These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“believes,” “estimates,” “anticipates,” “expects,” “intends,”
“may,” “will,” or “should” and include statements argenx makes
concerning the intended results of its strategy. By their
nature, forward-looking statements involve risks and uncertainties
and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. argenx’s actual results
may differ materially from those predicted by the forward-looking
statements as a result of various important factors, including
argenx’s expectations regarding its the inherent uncertainties
associated with competitive developments, preclinical and clinical
trial and product development activities and regulatory approval
requirements; argenx’s reliance on collaborations with third
parties; estimating the commercial potential of argenx’s product
candidates; argenx’s ability to obtain and maintain protection of
intellectual property for its technologies and drugs; argenx’s
limited operating history; and argenx’s ability to obtain
additional funding for operations and to complete the development
and commercialization of its product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in argenx’s U.S. Securities and Exchange Commission (SEC)
filings and reports, including in argenx’s most recent annual
report on Form 20-F filed with the SEC as well as subsequent
filings and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. argenx undertakes no obligation to publicly update or
revise the information in this press release, including any
forward-looking statements, except as may be required by law.
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Apr 2024 to May 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From May 2023 to May 2024